PUBLIC COMPANY
save$ARQTArcutis Biotherapeutics, Inc.
$ARQT25.16-0.51%Westlake Village, CA, USupdated 20h ago
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Marketed1pre_registration
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- phase1Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
- phase3Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
- phase3Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
- phase2Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
- phase3Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
- phase3Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
- phase3Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
🐶 Hiring Signal
next earnings Oct 27, 2026
News
no news has mentioned this company yet
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that